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Abstract 
Background: Little is known about the efficacy of first and and second-line antiretroviral therapies (ART) for HIV-1 
infected children in resource limited Southeast Asian settings. Previous studies have shown that orphans are at a 
higher risk for virological failure (VF) in Cambodia. Consequently most of them required transfer to second-line ART. 
We assessed the factors associated with VF among HIV-1 infected children who were either under first-line (mostly 
3TC + D4T + NVP) or under second-line (mostly ABC + DDI + LPV) therapies at a referral hospital in Cambodia.
Methods: A case-control study was conducted from February to July 2013 at the National Pediatric Hospital among 
HIV-1 infected children (aged 1–15 years) under second-line ART (cases) or first-line (matched controls at a ratio of 
1:3) regimens. Children were included if a HIV-1 RNA plasma viral load (VL) result was available for the preceding 
12 months. A standardized questionnaire explored family sociodemographics, HIV history, and adherence to ART. 
Associations between VF (HIV-1 RNA levels ≥1000 copies/ml) and the children’s characteristics were assessed using 
bivariate and multivariate analyses.
Results: A total of 232 children, 175 (75.4 %) under first-line and 57 (24.6 %) under second-line ART, for a median of 
72.0 (IQR: 68.0–76.0) months, were enrolled. Of them, 94 (40.5 %) were double orphans and 51 (22.0 %) single orphans, 
and 77 (33.2 %) were living in orphanages. A total of 222 children (95.6 %) were deemed adherent to ART. Overall, 18 
(7.7 %; 95 % CI 4.6–11.9) showed a VF, 14 (8.6 %; 95 % CI 4.8–14.0) under first-line and 4 (7.0 %; 95 % CI 1.9–17.0) under 
second-line ART (p = 0.5). Their median CD4 percentage was 8 % (IQR 2.9–12.9) at ART initiation. Children under 
second-line ART were older; more often double orphans, and had lower CD4 cell counts at the last control.
In the multivariate analysis, having the last CD4 percentage below 15 % was the only factor associated with VF for ART 
regimen separately or when combined (OR 40.4; 95 % CI 11–134).
Conclusions: The pattern of risk factors for VF in children is changing in Cambodia. Improved adherence evaluation 
and intensified monitoring of children with low CD4 counts is needed to decrease the risk of VF.
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Background
By the end of 2013, of the 35.3 million people living with 
HIV in the world, 3.3 million were children. Improved 
access to services for prevention of mother-to-child 
transmission of HIV and improved availability of antiret-
roviral therapy (ART) have reduced the number of new 
HIV infections by 50 % and AIDS-related deaths by 20 % 
among children [1].
The number of children, less than 15  years, receiv-
ing ART in low-and middle-income countries increased 
from 566,000 in 2011 to 630,000 in 2012 but this increase 
remains far below that of adult patients [2, 3]. An esti-
mated 200,000 children with HIV live in Southeast Asia. 
Of them, 46,000 (23 %) receive ART, 21,000 were newly 
infected and 13,000 died in 2012 [4]. Good ART out-
comes have been reported from pediatric HIV/AIDS 
programs in low resource settings, comparable to those 
in high-income countries [5].
Children on ART pose crucial concerns in low 
resources settings [4, 5]. First, they require long-term 
therapy with unknown long-term side effects. Second, 
the scarcity of pediatric formulations and inadequate 
dosage guidelines for specific antiretrovirals (ARVs) and 
age groups may contribute to suboptimal plasma drug 
levels. Third, these children, especially teenagers, have 
decreased adherence to treatment. All these factors can 
result in rapid HIV drug resistance (HIV DR).
Children are twice as likely to experience virological 
failure (VF) to ART as compared with adults after 5 years 
of treatment and 13–53 % of them are expected to expe-
rience VF within the first year [6]. Therefore, they are at 
a higher risk of developing HIV DR, particularly if failure 
is diagnosed late [7]. HIV DR genotyping has become a 
standard of care in HIV infection management in devel-
oped countries [6] but its availability remains infrequent 
in the developing world [8].
Over the last decade, Cambodia’s human immunodefi-
ciency virus (HIV) program (NCHADS, National Center 
for HIV/AIDS, Dermatology and STD, Sexually Trans-
mitted Diseases) has been quite successful. The preva-
lence of HIV infection decreased from 2.4 % in 1998 to 
0.7 % in 2012 [9, 10]. The number of children living with 
HIV was estimated at 8512 and 4052 (47.6 %) were under 
ART in 2013 [9, 11, 12].
Several studies have reported the high effectiveness 
of ART in Cambodia for durations ranging from 12 to 
36  months [13–15]. Compared to ART children, pre-
ART children have a 4:1 mortality ratio and a 13:8 ratio 
of loss to follow-up [14, 15]. Being an orphan was consid-
ered an important predictor of VF [13].
Data on pediatric treatment monitoring and resist-
ance in first-line and second-line failures are lim-
ited in Cambodia. Based on the WHO 2010 pediatric 
guidelines, without routine viral load monitoring, treat-
ment failure were misclassified for children on first-line 
therapy [16, 17]. In addition, extensive drug resistance 
to first-line ART was described among 51 HIV-infected 
children, who were undetected as first-line ART fail-
ures under the WHO 2010 guidelines [18]. Similarly 
the HIV/Hepatitis laboratory of the Pasteur Institute in 
Cambodia reported the occurrence of mutations in chil-
dren from routine samples collected between Decem-
ber 2004 and January 2011 [17]. Since then, children 
were switched to second-line ART primarily based on 
clinical and immunological criteria, following national 
pediatric guidelines [19]. This is the first study to com-
pare the current profile of children under first-line and 
second-line ART in Cambodia and to assess the evolu-




The study was authorized by the National Pediatric Hos-
pital (NPH) authorities. Ethical approval was granted 
by the Cambodian and Lao Medical Ethics Committees 
because the study was conducted in Cambodia as part 
of a master study from the “Institut de la Francophonie 
pour la Médecine Tropicale” (IFMT, Vientiane, Laos). 
The study complied with the Cambodian law on personal 
protection of people living with HIV. Children and par-
ents/guardians were informed about the study in Khmer 
language and given an information paper describing it. 
They were included if they consented to participate and if 
their parent/guardians gave informed consent in writing. 
Confidentiality was guaranteed and interviews were con-
ducted by a clinical investigator in a private room. Atten-
tion was paid to not disclosing the reason for the visit, or 
the child’s status, during home visits. Data was recorded 
anonymously.
Study site
The study was conducted from February to July 2013 in 
the HIV clinic of the NPH in Phnom Penh during chil-
dren’s routine visits. The NPH was the first setting to 
start ART in 2004. At the time of the study NPH provided 
ART to 1300 HIV children, including 107 on second-line 
ART. Children were monitored every 3  months at the 
outpatient department for clinical status, adherence and 
counseling and CD4 cell counts.
Plasma HIV-1 viral load (VL) was measured accord-
ing to the Cambodian National Guidelines for Manage-
ment of Pediatric HIV recommendation once within the 
first 6 months of starting ART and then every 12 months. 
HIV-1 genotyping was not routinely available for 
children.
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Study procedures and questionnaires
Cambodian children between 12  months and 15  years 
attending the HIV clinic were eligible if they had been 
under second-line ART for at least 6  months and if VL 
had been performed after the start of second–line line 
and within the 12  months prior to the survey. For each 
child on second-line ART, 3 children on first-line ART 
and of a similar age ±1 years and with a VL conducted 
within the last 12 months were randomly selected among 
those attending the clinic the same day.
An interview was conducted with the parent/guardian 
and child in Khmer language. The questionnaire included 
sociodemographic items about the household, parental 
resources (if available), access to care and compliance 
with ART (Additional file 1).
For children younger than 7  years, the parent/guard-
ians were asked questions. Children over 7 years old were 
asked these questions directly in the presence of their 
parent/guardian.
Data relating to the child’s HIV status, disease history 
and treatment was retrieved from the hospital records 
after the interview. Adherence to treatment was evalu-
ated by the recall of missed medication intake during the 
previous 4 days, within the previous month and by count-
ing the tablets at home. The tablet counting was per-
formed after parental agreement, on appointment with 
parent/caregivers within 1  month after the first meet-
ing. Adherence variables were dichotomized as complete 
(100 %) vs. incomplete (<100 %) [20].
Definitions
Single orphans were children who had lost one parent 
and double orphans were children who had lost both.
Virological failure was defined as plasma HIV-1 RNA 
level ≥1000 copies/mL. For children on second-line ther-
apy, the VL had to be done after the start of second-line 
treatment in order to be considered as second-line failure 
[21, 22]. Due to limited resources and NPH procedures 
VL was not tested a second time.
Sample size
Using Stata Version 8 (Stata Cooperation, College Sta-
tion, TX), a required sample size of 250 people was calcu-
lated using a 1:3 ratio between second-line and first-line 
children. Based on previous reports of effectiveness of 
first-line ART and an estimate of current VF on second-
line (unpublished data), VF was expected around 6  % 
among second-line ART children and 25 % among first-
line ART children. The sample size was adapted by esti-
mating the number of second-line treatment patients 
attending the clinics over 4 months that could be enrolled 
(i.e.: 40–60 patients). with 10 % precision, alpha = 0.05, 
power 90 %.
Data management and analysis
Data was entered in Epidata freeware (http://www.epi-
data.dk, Odense, Denmark) and cross-checked against 
original data sheets. Analyses were carried out with 
Stata software, Version 8 (Stata Corporation, College 
Station, TX, USA). Chi2 or Fisher’s exact test were used 
to assess associations between categorical variables as 
appropriate, and Student’s t test for two normally dis-
tributed continuous variables or Kruskal–Wallis as 
appropriate. P ≤ 0.05 was considered significant. Asso-
ciations between VL and children’s characteristics were 
initially measured using bivariate analyses (age, sex, 
socio-economic conditions, schooling, time since diag-
nosis and ART, and adherence to treatment, initial CD4 
cells count, type of treatment and weight gain over the 
preceding year).
Multivariate analyses between VL and children’s char-
acteristics were conducted initially for each treatment 
group, then combining both treatment groups, by intro-
ducing into the model the variables significantly associ-
ated with VL (those with p values <0.2, Tables 1, 2). Then, 
a back-step selection procedure using odd ratios was 
used to leave only those with a p value <0.05 in the final 
model.
We have attempted to report the study according to the 
STROBE guidelines (Additional file 2).
Results
Characteristics of the study population
A total of 250 children (63 and 187 on second-line and 
first-line, respectively) were eligible for the survey. 
Of these, 232 (92.8  %) had VL recorded within the last 
12 months and were analyzed including 175 (75.4 %) on 
first-line and 57 (24.6 %) on second-line ART (Fig. 1).
A total of 157 (62 %) children had a VL done during the 
survey including 37 (58.7 %) second-line and 120 (64.1 %) 
first-line. The median time between VL and survey 
assessment was 4.0 months (inter quartile range: 3–5).
Their social and treatment characteristics are shown in 
Tables 1 and 2, and supplementary tables.
Among them, 94 (40.5  %) were double orphans, 51 
(22.0 %) single orphans and 77 (32.2 %) lived in orphan-
ages. A total of 79 children (34.1  %) were cared for by 
their mothers, while 61 (27.6  %) by another member of 
the family, and 89 (38.4  %) by non-family. The median 
time on ART was shorter for children of the first-line 
group vs. for children of the second-line group (70.5 
[43.9–90.8] months and 81.0 [71.4–92.5] months respec-
tively, p  =  0.001). The majority were WHO Stage II 
(N  =  129, 55.6  %) and the median CD4 percentage in 
all patients was 8 % (IQR 2.9–12.9), at initiation of ART 
(Supplementary table). The median interval between 
diagnosis and ART onset was 11.8 (IQR 9.4–14.2) 
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months. Median CD4 percentage did not differ between 
groups at initiation of ART (Table 2).
A total of 57 children were transferred to second-
line ART within a median time of 36.5 (IQR 19.6–55.9) 
months. Children on second-line were more often dou-
ble orphans (p = 0.06), aged over 7 years (p = 0.01) and 
living in orphanages than children in the first-line group. 
They had a significantly lower CD4 cell count at the last 
control.
First-line treatments began mostly with 3TC + D4T +  
NVP (62.9  %) while ABC  +  DDI  +  LPV (54.4  %) was 
the most frequent second-line regimen at the time of 
the survey. Full adherence to ART was self-reported for 
226 children (97.4  %) and ascertained for 222 children 
(95.6  %) by counting pills at home or at the institution. 
No decrease in adherence was reported among children 
on second-line.
Overall, 18 (7.7 %; 95 % CI 4.6–11.9) showed a VF, 14 
(8.6  %; 95  % CI 4.8–14.0) under first-line and 4 (7.0  %; 
95  % CI 1.9–17.0) under second-line ART (p  =  0.5).A 
total of 155 families (62.0  %) reported breastfeeding 
(61; 32.2 % vs. 31; 49.2; p = 0.04). The mean duration of 
breastfeeding was 7.4 months (95 % CI 7.0–7.9). Families 
were unable to answer the question about HIV prophy-
laxis during pregnancy.
The mean global weight gain within the previous year 
of treatment was 3.7  kg (95  % CI 3.3–4.0) without dif-
ference between the groups (3.8 kg; 95 % CI 3.4–4.1 and 
3.3 kg; 95 % CI 2.0–4.5, p = 0.3, for first-line and second-
line ART, respectively). The absence of weight gain over 
the previous year was not associated with VF. Of 6 (2.5 %) 
children with no weight gain, only one (0.4 %) had a VF.
In multivariate analysis, having the last CD4 percent-
age below 15  % was the only factor associated with VF 
for children on first-line treatment (OR 44.9 95  % CI 
10.2–196.2) and the second-line group (OR 69; 95 % CI 
4.7–995) or when combining first and second-line group 
together (OR 40.4; 95 % CI 11–134) (Table 3).
Table 1 Socio-demographic characteristics of children on first-line and second-line ART at National Pediatric Hospital
Numbers and (percentages). Median and (interquartile range)
a 76 were “caregivers” from the orphanage
First-line Second-line p
n = 175 % n = 57 %
Female 91 52.0 24 42.1 0.1
Age median, years 11.4 (IQR: 9.2–13.5) 11.4 (IQR: 9.4–13.8) 0.4
Age up to 7 years 151 86.3 56 98.2 0.01
Orphan both parents 65 37.1 29 50.9 0.06
Orphan mother 10 5.7 2 3.5 0.3
Orphan father 31 17.7 8 14.0
Living in orphanage 50 28.6 27 47.4 0.009
Child education
 Not attending school (>5 years. n = 219) 6 3.4 0 0.0
 Primary 106 60.6 43 75.4 0.2
 Secondary 46 26.3 12 21.1
Father low skilled worker (n = 191) 60 34.3 12 21.1
Mother low skilled (n = 126) 60 47.6 15 26.3
In charge of the child
 Mother 78 44.6 23 40.4 0.3
 Father 6 3.4 1 1.8
 Grandmother 24 13.7 5 8.8
 Relatives 3 1.7 0 0.0
 Othersa 64 36.6 28 49.1
Family assets and characteristics
 Own their house (n = 149) 87 58.4 18 31.6 0.2
 Number of people living in same house 5.1 3.3 4.6 8.1
 Daily family expense USD (n = 155) 3.3 (3.0–3.6) 3.2 (2.5–3.9) 0.4
 Have a TV set 120 80.5 29 50.9 0.01
 Have a car 5 3.4 1 1.8 0.8
 Have a motorbike 113 75.8 27 47.4 0.8
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Discussion
Early studies on ART in Cambodia demonstrated high 
effectiveness both in adults and children with follow-up 
ranging from 12  months to 4  years [13–15, 23–28]. At 
that time, reports about children’s ART chiefly expressed 
concerns about the challenges of detecting treatment 
failures using only immunological and clinical criteria 
[16]. Later, with the development of HIV genotypic resist-
ance testing, high resistance mutations were reported in 
children with virological failure on first-line ART [17, 18]. 
However this testing was not yet routinely available. Our 
study confirms the global effectiveness of both first-line 
and second-line regimens for children over a long dura-
tion of follow-up (73 months), and a high level of adher-
ence evidenced by routine tools. Second-line children 
who previously failed the first ART line had a similar rate 
of VF as children on first-line treatment. Despite these 
good results, a crucial issue for children with VF on sec-
ond-line treatment is the lack of further options for ART 
in Cambodia and other countries. Besides, children on 
the second-line regimen had a lower median CD4 per-
centage at the last check. Improved measurements of 
adherence and access to genotypic testing for drug resist-
ance, are urgently needed to provide high risk children 
with the best treatment options.
Our study confirms a high level of adherence among 
children currently on ART using the routine tools. Chil-
dren on second-line, previously described as poorly 
adherent, now appear to be fully compliant with treat-
ment. Such improvement was probably due to the 
implementation of home visits, called home-based care 
(but this issue was not documented in the survey), and 
the careful attention that was paid to adherence during 
all routine visits at the hospital. The second reason for 
improved adherence was probably that half of children 
live in orphanages which are commited to supporting 
adherence to ART and to routine medical follow-up. 
However, these good adherence results could be ques-
tioned given the occurrence of VF among children on 
second-line ART. The quality of adherence was probably 
Table 2 Treatment characteristics of  children on  first-line 
and second-line ART at National Pediatric Hospital
Numbers and (percentages). Median and (interquartile range)
CI Confidence interval
First-line Second-line p
n = 175 % n = 57 %
Clinical status at ART onset
 WHO Stage I 37 21.1 5 8.8 0.06
 WHO Stage II 93 53.1 36 63.2
 WHO Stage III 44 25.1 14 24.6
 WHO Stage IV 1 0.6 2 3.5
 Initial CD4 cells (%) 9.1 (3.9–12.9) 7.9 (2.5–12.8) 0.1
 Initial CD4 <15 % 147 84.0 52 91.2 0.17
 Time before ART 
onset (months)
2.6 (1.1–15.7) 2.5 (1.2–8.3) 0.1
At the time of survey












 Time between 
VL and survey 
(months)
0.1 (0.1–4) 0.1(0.1–4) 0.7
 Non-adherence 
to ART
6 3.4 0 0.1
 Weight gain over 
1 year (kg)
3.8 (3.5–4.2) 3.5 (2.7–4.2) 0.3
 Last CD4 cells (%) 27.8 (23.6–
31.8)
22 (19.1–27) <0.001
 CD4 cells <15 % 2 1.1 6 10.5
Initial first-line treatment
 3TC + D4T + NVP 93 53.1 53 93.0
 3TC + AZT + NVP 36 20.6
 3TC + D4T + EFV 30 17.1 4 7.0
 3TC + AZT + EFV 14 8.0
 3TC + AZT + LPV 1 0.6
 3TC + D4T + LPV 1 0.6
Current second-line treatment
 ABC + DDI + LPV 31 54.4
 3TC + TDF + LPV 13 22.8
 3TC + DDI + LPV 3 5.3
 3Tc + AZT + LPV 3 5.3
 ABC + TDF + LPV 3 5.3
 3TC + ABC + LPV 2 3.5



















Fig. 1 Flow chart of first and second-line ART children enrolled in 
National Pediatric Hospital, Cambodia


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 8 of 10Barennes et al. BMC Res Notes  (2016) 9:69 
overestimated using the routine tools (self reporting and 
pill counting during home visits). Health staff and the 
investigation team reported that parents/caregivers, 
being informed in advance about visits, prepared and 
presented to the health worker the expected number of 
pills. The precise reasons were not documented but could 
have been the fear of reprimands or that treatment would 
be discontinued or changed. Similar observations were 
reported in Ethiopia where routine adherence rates in 
the preceding 7 days decreased from 93.3 to 34.8 % using 
unannounced home-based pill counts [29]. Due to ethi-
cal concerns and fear of stigmatization [20], conducting 
unannounced visits was considered inappropriate by our 
study team.
With the 18 children who experienced a VF, it was not 
possible to quantify the rate of resistance to antiretro-
viral drugs since genotyping tests were not available, a 
limitation of our study. However, other studies provided 
information regarding HIV mutations among children 
with VF during the same period. Between December 
2004 and January 2011, in Cambodia, all genotypic tests 
for HIV drug resistance mandated by the provincial capi-
tal were conducted at the Pasteur Institute. Assuming a 
lower threshold of VF (viral load ≥250 copies/mL), geno-
typic testing performed on 233 children revealed that 33 
(14.1 %) harboured the Q151M and 17 (7.2 %) the K65R 
mutations which confer resistance to a large range of 
nucleoside reverse transcriptase inhibitors (NRTIs) [17]. 
This trend was confirmed by a similar study conducted 
at the Angkor Hospital for Children in Siem Reap [18]. 
Of 51 viremic children (>1000  copies/mL) all but one 
harbored drug resistance mutations to NRTIs and non-
nucleoside reverse transcriptase inhibitors (NNRTIs), 
and half had more than 4 mutations. A quarter had 
multi-resistant mutations and 9 (18 %) high-level resist-
ance-predicting mutations to subsequent therapy options 
including didanosine (DDI), abacavir (ABC), etravirine 
(ETR), and tenofovir (TDF) [18]. Emergence of these 
mutations is a critical issue in resource-limited settings 
where NRTI molecules available for second-line regi-
mens remain limited.
The continuation of failing ART regimens is of concern 
since it will result in an accumulation of resistance that 
will hamper the effectiveness of subsequent regimens. 
The scaling up of drug resistance testing has been pro-
posed [18, 28, 30].
Among the children who attended the HIV clinic, the 
percentage living in orphanages increased from 10 % in 
2007 up to 32.2 % in 2013 [20]. In our study, the num-
ber of orphans tended to be higher among children on 
second-line regimens. Being an orphan was previously 
associated with more frequent VF [31] and subsequent 
transition to second-line ART. In our study, being cared 
for by one’s mother was a non-protective factor for VF in 
univariate analysis. This was probably related to the dif-
ficult situation of the families living with HIV, the major-
ity of whom are living in extreme poverty (Table 1). So, 
the best way to improve ART success would probably be 
to improve the economic and social conditions of those 
living with HIV. This is supported by the protective fac-
tor (having a TV set) identified in univariate analysis, 
suggesting better access to information, prevention and 
care.
Effective interventions to reduce poverty are critical in 
mitigating the negative impacts of HIV and AIDS on chil-
dren and households [32].
Limitations
This study has several limitations. The first limitation is 
the small sample size due to time and budget constraints. 
The second limitation was the fact that the number and 
frequency of VL done per child, that could have affected 
the results, could not be addressed. However health staff 
were following the national guidelines on VL, which 
probably may have reduce this limitation. The third 
limitation was inability to conduct drug resistance tests 
as they were not covered by the ART program. Improv-
ing adherence support and availability of drug resistance 
testing are crucial to halt the rise in resistance mutations 
to ART drugs available in Cambodia.
Conclusions
Children on second-line are more often double orphans, 
aged over 7 years and living in orphanages than children 
in the first-line ART in the National Pediatric hospital of 
Cambodia. The pattern of risk factors for VF is changing 
in Cambodia. The prevention of VF requires improving 
ART adherence and monitoring, better monitoring of 
children with low CD4 counts and access to routine viral 
load testing. Attention is needed to conflicting results of 
adherence and viral failure. The presence of VF in chil-
dren under second-line ART is a crucial issue in a coun-
try where no third line ART is available.
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